Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

09 May 2008
Shire opens new office in Norway

Shire plc announced today that it has extended its operations to Norway. The establishment of the Norwegian office will strengthen Shire’s position in the Nordic Market. This local office will better explore opportunities and ensure patient access to our human genetic therapies. We will be able to offer better services to both physicians and patients in order to increase the availability and enable future growth for Shire. Norway will also actively focus on involvement of Norwegian hospitals in future clinical trials. Mark Rothera, European and Regional Sales and Marketing Director of Shire’s HGT business commented, 'We are delighted to open an office in Norway. Erling Nordboe joined us from Merck Serono in January to become Country Manger for Norway. He is the first person to join our Nordic team after Roger Starkman who is our Area Director Nordic Region. They represent Shire Human Genetic Therapies' interests in the region which includes Denmark, Finland, Iceland, Norway and Sweden. We already have a significant and profitable franchise in Norway and this is set to grow in the coming years. The Nordic region headquarter is in Stockholm where we also have staff supporting core medical functions for the division such as Outcomes Surveys'. For further information please contact: Investor Relations Cléa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 SHIRE PLC Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website:

« Back to Shire news

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device